ETC

Recommend
Index
  • Paxerontine SR Tab. 12.5mg

    Paxerontine SR Tab. 12.5mg

    Ingredient

    Paroxetine Hydrochloride

    Content

    12.5mg

    Indication

    1) Treatment of major depressive disorder
    2) Treatment of panic disorder, with or without agoraphobia
    3) Treatment of social anxiety disorder, also known as social phobia
    4) Treatment of premenstrual dysphoric disorder (PMDD)

  • Paxerontine SR Tab. 25mg

    Paxerontine SR Tab. 25mg

    Ingredient

    Paroxetine Hydrochloride

    Content

    25mg

    Indication

    1) Treatment of major depressive disorder
    2) Treatment of panic disorder, with or without agoraphobia.
    3) Treatment of social anxiety disorder, also known as social phobia.
    4) Treatment of premenstrual dysphoric disorder (PMDD).

  • Pemzayre® tablet 13.5mg

    Pemzayre® tablet 13.5mg

    Ingredient

    1 Tab(240.0mg) contains, pemigatinib (In-house spec.) 13.5mg

    Content

    White to off-white round tablet, one side debossed with “I”, the other side with “13.5”.

    Indication

    The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.

  • Pemzayre® tablet 9mg

    Pemzayre® tablet 9mg

    Ingredient

    1 Tab(160.0mg) contains, pemigatinib (In-house spec.) 9mg

    Content

    White to off-white oval tablet, one side debossed with “I”, the other side with “9”.

    Indication

    The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.

  • Pemzyre® tablet 4.5mg

    Pemzyre® tablet 4.5mg

    Ingredient

    1 Tab(80.0mg) contains, pemigatinib (In-house spec.) 4.5mg

    Content

    White to off-white round tablet, one side debossed with “I”, the other side with “4.5”.

    Indication

    The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.

TOP